Phase I study of (6R)-5, 10-dideazatetrahydrofolate: A folate antimetabolite inhibitory to de novo purine synthesis

Journal of the National Cancer Institute

Volumn 85, Issue 14, 1993, Pages 1154-1159

  Ray, Margaret S ^a   Muggia, Franco M ^a   Leichman, C Gail ^a   Grunberg, Steven M ^a   Nelson, Robert L ^b   Dyke, Richard W ^b   Moran, Richard G ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; LOMETREXOL; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; DRUG MONITORING; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; FOLATE METABOLISM; HUMAN; LIVER TOXICITY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PURINE SYNTHESIS; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLIC ACID ANTAGONISTS; HEMATOLOGIC DISEASES; HUMAN; LEUCOVORIN; MALE; MIDDLE AGE; NEOPLASMS; PURINES; SUPPORT, U.S. GOV'T, P.H.S.; TETRAHYDROFOLATES; TREATMENT OUTCOME;

EID: 0027179429     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.14.1154     Document Type: Article

References (17)

1. Sirotnak FM, DeGraw JI: Selective antitumor action of folate analogs. In Folate Antagonists as Therapeutic Agents (Sirotnak FM, Burchall JJ, Ensminger WD, et al, eds), vol 2. New York: Academic Press, 1984, pp 43-95
2. Rumberoer BG, Barrueco JR, Sirotnak FM: Differing specificities for 4-aminofo- late analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Res 50:4639-4643, 1990
3. Taylor EC, Harrington PJ, Fletcher SR, et al: Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10- dideaza-5,6,7,8-tetrahydroami nopterin J Med Chem 28:914-921, 1985
4. Beardsley GP, Moroson BA, Taylor EC, et al: A new folate antimetabolite 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333, 1989
5. Moran RG, Baldwin SW, Taylor EC, et al: The 6S- and 6R-diastereomers of 5,10- dideaza-5,6,7,8-tetrahydrofolale are equiac- tive inhibitors of de novo purine synthesis. J Biol Chem 264:21047-21051, 1989
6. Shih C, Grindey GB, Houghton PJ, et al In vivo antitumor activity of 5,10- dideazatetrahydrofolic acid (DDATHF) and its diastereomenc isomers. Proc Am Assoc Cancer Res 29:1125, 1988
7. Nelson R, Butler F, Dugan W, et al: Phase I clinical trial of LY2646I8 (didcaza- tetrahydrofolic acid; DDATHF). Proc ASCO 9:76, 1990
8. Taber LD, O’brien P, Bowsher RR, et al: Competitive particle concentration fluorescence immunoassay for measuring 5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) in serum. Clin Chem 37:254-260, 1991
9. Young CW, Currie V, Balter L, et al: Phase I and clinical pharmacologic study of LY 264618, 5,10-dideazatetrahydrofolate. Proc Am Assoc Cancer Res 31:177, 1990
10. Sessa C, DeJong J, Kern H, et al: Phase I study of lometrexol (LY 264618, DDATHF) given every 4 weeks. Ann Oncol 3:22, 1992
11. Pizzorno G, Cashmore AR, Moroson BA, et al 5,10-Dideazatetrahydrofolate (DDATHF) transport in CCRF-CEM and MA104 cell lines. J Biol Chem 268:1017-1023, 1993
12. Baldwin SW, Tse A, Gossett LS, et al: Structural features of 5, IO-dideaza-5,6,7,8- tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry 30:1997-2006, 1991
13. Pizzorno G, Sokoloski JA, Cashmore AR, et al: Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines. Mol Pharmacol 39:8589, 1990
14. Pizzorno G, Russello O, Cashmore AR, et al: Polyglutamation: An essential step in the activation of 5,10-dideazatetrahydro- foltc acid. Proc Am Assoc Cancer Res 31:339, 1990
15. Grindey GB, Alati T, Shih C. Reversal of the toxicity but not the antitumor activity of Lometrexol by folic acid. Proc Am Assoc Cancer Res 32:324, 1991
16. Alati T, Shih C, Pohland R, et al: Evaluation of the mechanism of inhibition of the toxicity, but not the antitumor activity of Lometrexol (DDATHF) by folic acid. Proc Am Assoc Cancer Res 33:407, 1992
17. Barredo J, Moran RG: Determinants of antifolate cytotoxicity: Folylpolyglutamate synthetase activity during cellular proliferation and development. Mol Pharmacol 42:687-694, 1992